MRPL44

Across TCGA pan-cancer cohorts, MRPL44 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MRPL44 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MRPL44 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL44 expression acts as an unfavorable survival marker.

UCS, CESC, and PRAD are the cancer types where MRPL44 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	II,III,IV	0.001	0.616	<.001	24	view →
CESC	DFS	Median	II,III,IV	0.184	0.705	.036	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	0.172	0.579	.010	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MRPL44–UCS (OS)

Open the UCS breakdown →